RJA
PBE icon

Raymond James & Associates’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Raymond James & Associates’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$481K Sell
6,891
-252
-4% -$17.4K ﹤0.01% 3136
2024
Q2 		$463K Buy
7,143
+167
+2% +$10.6K ﹤0.01% 3125
2024
Q1 		$451K Sell
6,976
-6,271
-47% -$408K ﹤0.01% 3114
2023
Q4 		$872K Buy
13,247
+7,268
+122% +$423K ﹤0.01% 2600
2023
Q3 		$341K Sell
5,979
-600
-9% -$36.6K ﹤0.01% 3119
2023
Q2 		$403K Buy
6,579
+453
+7% +$28.3K ﹤0.01% 3068
2023
Q1 		$385K Buy
6,126
+198
+3% +$12.8K ﹤0.01% 3075
2022
Q4 		$376K Sell
5,928
-282
-5% -$17.9K ﹤0.01% 3074
2022
Q3 		$366K Buy
6,210
+731
+13% +$45K ﹤0.01% 3054
2022
Q2 		$316K Sell
5,479
-6
-0.1% -$346 ﹤0.01% 3198
2022
Q1 		$340K Buy
5,485
+127
+2% +$7.75K ﹤0.01% 3335
2021
Q4 		$382K Sell
5,358
-898
-14% -$65K ﹤0.01% 3291
2021
Q3 		$468K Sell
6,256
-852
-12% -$64.9K ﹤0.01% 3113
2021
Q2 		$550K Hold
7,108
– – ﹤0.01% 3012
2021
Q1 		$525K Sell
7,108
-270
-4% -$20.4K ﹤0.01% 2978
2020
Q4 		$517K Sell
7,378
-6,393
-46% -$405K ﹤0.01% 2783
2020
Q3 		$780K Sell
13,771
-122
-0.9% -$7.17K ﹤0.01% 2331
2020
Q2 		$810K Buy
13,893
+5,162
+59% +$281K ﹤0.01% 2300
2020
Q1 		$406K Sell
8,731
-810
-8% -$42.2K ﹤0.01% 2565
2019
Q4 		$533K Sell
9,541
-7,014
-42% -$366K ﹤0.01% 2684
2019
Q3 		$784K Buy
16,555
+571
+4% +$29.3K ﹤0.01% 2338
2019
Q2 		$855K Sell
15,984
-34,712
-68% -$1.8M ﹤0.01% 2310
2019
Q1 		$2.8M Buy
50,696
+653
+1% +$34.5K ﹤0.01% 1553
2018
Q4 		$2.36M Buy
50,043
+36,991
+283% +$1.9M ﹤0.01% 1550
2018
Q3 		$776K Buy
13,052
+1,435
+12% +$83.7K ﹤0.01% 2421
2018
Q2 		$636K Buy
11,617
+540
+5% +$27.5K ﹤0.01% 2519
2018
Q1 		$545K Buy
11,077
+360
+3% +$18.4K ﹤0.01% 2508
2017
Q4 		$505K Sell
10,717
-1,150
-10% -$53.9K ﹤0.01% 2529
2017
Q3 		$593K Sell
11,867
-32
-0.3% -$1.52K ﹤0.01% 2382
2017
Q2 		$543K Buy
11,899
+1,332
+13% +$57.5K ﹤0.01% 2364
2017
Q1 		$447K Sell
10,567
-1,208
-10% -$50.6K ﹤0.01% 2454
2016
Q4 		$457K Buy
11,775
+35
+0.3% +$1.41K ﹤0.01% 2393
2016
Q3 		$493K Sell
11,740
-1,734
-13% -$71.2K ﹤0.01% 2295
2016
Q2 		$498K Buy
13,474
+780
+6% +$30.6K ﹤0.01% 2109
2016
Q1 		$486K Buy
12,694
+1,657
+15% +$64.4K ﹤0.01% 2057
2015
Q4 		$558K Sell
11,037
-19,481
-64% -$963K ﹤0.01% 1934
2015
Q3 		$1.4M Sell
30,518
-4,907
-14% -$274K 0.01% 1421
2015
Q2 		$2.07M Buy
35,425
+1,055
+3% +$60.3K 0.01% 1293
2015
Q1 		$1.9M Sell
34,370
-566
-2% -$30.6K 0.01% 1268
2014
Q4 		$1.75M Sell
34,936
-1,151
-3% -$56.3K 0.01% 1233
2014
Q3 		$1.67M Sell
36,087
-1,237
-3% -$55.7K 0.01% 1187
2014
Q2 		$1.63M Buy
37,324
+3,085
+9% +$125K 0.01% 1209
2014
Q1 		$1.43M Buy
34,239
+2,463
+8% +$105K 0.01% 1220
2013
Q4 		$1.18M Buy
31,776
+14,333
+82% +$514K 0.01% 1238
2013
Q3 		$612K Sell
17,443
-988
-5% -$32.7K 0.01% 1502
2013
Q2 		$532K Buy
+18,431
New +$524K 0.01% 1494

Other funds holding PBE

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CW
CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Raymond James & Associates's PBE Position: Q3 2024 in Review

Raymond James & Associates reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 3.5% in Q3 2024, selling an estimated $17.4K and leaving 6,891 shares worth $481K. The position accounts for ﹤0.01% of the portfolio, ranked #3136.

Raymond James & Associates first reported a position in PBE in Q2 2013 and has held it in 46 quarters since. The position peaked at $2.8M in Q1 2019. 102 funds tracked by Wall St. Rank hold PBE as of Q3 2024.

  • Raymond James & Associates held 6,891 shares of Invesco Biotechnology & Genome ETF worth $481K as of Q3 2024.
  • Raymond James & Associates sold 252 Invesco Biotechnology & Genome ETF shares in Q3 2024, an estimated $17.4K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3136 holding.
  • Raymond James & Associates first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Invesco Biotechnology & Genome ETF position peaked at $2.8M in Q1 2019.
  • 102 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.